Abstract Number: 0517 • ACR Convergence 2025
Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
Background/Purpose: Fatigue affects 70% of primary Sjögren's syndrome (pSS) patients, but its mechanisms remain unclear. We investigated clinical predictors and gut microbiota associations in pSS-related…Abstract Number: 0299 • ACR Convergence 2025
Interpreting Myositis Autoantibody Line-Blot Immunoassays in Real-World Settings: Implications for Diagnostic Accuracy for Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) present with diverse clinical features and disease courses. The myositis autoantibody line blot immunoassay (LIA) has advanced IIM diagnostics and…Abstract Number: 2503 • ACR Convergence 2025
Validation of a Composite Biomarker Score To Predict Modified Rodnan Skin Score: Insight From Autologous Stem Cell Transplantation International Scleroderma trial
Background/Purpose: Skin fibrosis is a cardinal manifestation of diffuse cutaneous systemic sclerosis (dcSSc) and is routinely measured via the modified Rodnan skin score (mRSS); however,…Abstract Number: 2302 • ACR Convergence 2025
Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease
Background/Purpose: Patient-reported outcomes (PROs) measure a patient’s health-related quality of life. The role of ESSPRI and PROMIS measures in identifying subsets of patients with Sjogren’s…Abstract Number: 2028 • ACR Convergence 2025
Behçet’s Syndrome Beyond Endemic Borders: A 24-Year Longitudinal Analysis of Mortality in a Diverse South American Cohort
Background/Purpose: Behçet’s syndrome (BS) is a chronic, relapsing vasculitis that contributes substantially to morbidity and mortality, primarily due to vascular and neurological complications. Most of…Abstract Number: 1665 • ACR Convergence 2025
Comparative Effectiveness of Biologic Versus Conventional Therapy in Uveitis with Systemic Rheumatic Diseases: Real-World Evidence from a Propensity-Matched Cohort
Background/Purpose: Uveitis is a vision-threatening manifestation of systemic rheumatic diseases. While conventional immunosuppressants are typically first-line, biologics are often reserved for refractory cases. Long-term real-world…Abstract Number: 1486 • ACR Convergence 2025
Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Background/Purpose: Patients (pts) with systemic lupus erythematosus (SLE) have a significantly increased risk of atherosclerotic cardiovascular disease (ASCVD). EULAR recommends a comprehensive assessment and management…Abstract Number: 1158 • ACR Convergence 2025
Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
Background/Purpose: Heterozygous loss-of-function mutations in CTLA4 cause a spectrum of immune dysregulation, characterized by hypogammaglobulinemia, autoimmune cytopenias, and lymphoproliferation, yet penetrance and expressivity remain highly…Abstract Number: 0621 • ACR Convergence 2025
Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystemic autoimmune disease. Pleuropulmonary (PP) manifestations, including pleural effusion (PE), interstitial lung disease (ILD), pulmonary hypertension (PH), shrinking…Abstract Number: 0516 • ACR Convergence 2025
Association between anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies and lymphoma in primary Sjögren Disease (SD)
Background/Purpose: There is an unmet clinical need for identification of novel biomarkers of systemic complications and lymphoma in primary Sjögren disease (SD). Anti-cytosolic 5'-nucleotidase 1A…Abstract Number: 0251 • ACR Convergence 2025
Impact of Mepolizumab on Idiopathic Hypereosinophilic Syndromes: Preliminary Analysis of a Monocentric Retrospective Cohort
Background/Purpose: Idiopathic hypereosinophilic syndromes (iHES) are a group of disorders characterized by persistent eosinophilia and eosinophil-mediated organ damage. Mepolizumab, an anti-interleukin-5 monoclonal antibody, has proven…Abstract Number: 2496 • ACR Convergence 2025
Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
Background/Purpose: Evaluating disease modification in systemic sclerosis (SSc) is challenging and requires long term studies. This is especially relevant to limited cutaneous (lc)SSc where severe…Abstract Number: 2245 • ACR Convergence 2025
Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study
Background/Purpose: Cardiovascular diseases (CVD) are the first cause of death in patients with rheumatoid arthritis (RA). The guidelines recommend risk prediction in all RA patients.…Abstract Number: 2023 • ACR Convergence 2025
Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Background/Purpose: Anti-Ro52 antibodies are frequently detected in patients with systemic autoimmune rheumatic diseases (SARDs). Emerging evidence suggests a potential link between isolated anti-Ro52 positivity and…Abstract Number: 1664 • ACR Convergence 2025
Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression
Background/Purpose: There are no FDA-approved therapies for cardiac sarcoidosis (CS), a disease associated with high morbidity and mortality. Treatment typically consists of glucocorticoids and off-label…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 38
- Next Page »